Latest Breaking News On - உலகளாவிய பதிவு ஆவணம் - Page 5 : comparemela.com
INVENTIVA: Inventiva announces major recruitments to accelerate the development of lanifibranor in NASH
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Innate Pharma Reports First Half 2021 Financial Results and Business Update
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
CARMAT Reports Its 2021 Half-year Results and Issues an Update on Its Latest Progress and Main Strategic Objectives
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Atari S A : A transition year and implementation of a new strategy allying premium games, Atari VCS, Blockchain/NFTs and Licensing
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Inventiva announces the implementation of an At-The-Market program in the United States
Daix (France), August 2, 2021 (GLOBE NEWSWIRE) – Inventiva S.A. (NASDAQ: IVA – EURONEXT PARIS: IVA) (the “
Company”), a clinical-stage biotechnological company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the implementation of an At-The-Market (“
ATM”) program allowing the Company to issue and sell, including with unsolicited investors who have expressed an interest, ordinary shares in the form of American Depositary Shares (“
ADS”), each ADS representing one ordinary share of Inventiva, with aggregate gross sales proceeds of up to $100,000,000 (subject to a regulatory limit of 20% dilution and within the limits of the investors requests expressed in the context of the program), from time to time, pursuant to the t